Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Penpulimab - Akeso Biopharma/Chia Tai Tianqing Pharmaceutical Group

Next Previous
X
Search
Drug Profile

Penpulimab - Akeso Biopharma/Chia Tai Tianqing Pharmaceutical Group

Alternative Names: AK 105 - Akeso Biopharma/Chia Tai Tianqing Pharmaceutical Group; Anniko

Latest Information Update: 13 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akeso Biopharma
  • Developer Akeso Biopharma; Beijing Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group; Fudan University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nasopharyngeal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hodgkin's disease; Nasopharyngeal cancer; Non-small cell lung cancer
  • Phase III Liver cancer
  • Phase II Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Neuroendocrine tumours; Pancreatic cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Thyroid cancer; Urogenital cancer
  • Phase I/II Mesothelioma; Oesophageal cancer; Thymoma; Uterine cancer

Most Recent Events

  • 31 May 2024 Updated efficacy and adverse events data from a phase II trial in Nasopharyngeal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 01 May 2024 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School and Chia Tai Tianqing Pharmaceutical completes a phase-II clinical trial in Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease, First-line therapy) in China (IV) (NCT05493995)
  • 23 Jan 2024 Phase-I/II clinical trials in Cholangiocarcinoma (Combination therapy) (IV) before January 2024 (Akeso Biopharma pipeline, January 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top